CEO Letter

Home>Tag:CEO Letter
Jan 11 2024

Halberd Corporation 2023 Year-End CEO Update and 2024 Goals

By |2024-01-10T20:13:22-05:00January 11th, 2024|Featured, Investor News, News|0 Comments

Jackson Center, PA, January 11, 2024 -- Halberd Corporation (OTC: HALB) made significant advances in its technology development and accomplished major business goals during the second half of 2023. 2023 ACHIEVEMENTS Halberd received from the CDC two sets of antibiotic resistant bacteria and fungi (a total of 60 samples) on which to test its proprietary ...

Jul 20 2023

Halberd Corporation 2Q23 CEO Letter

By |2023-07-19T20:54:59-04:00July 20th, 2023|Featured, Investor News, Update Letter|0 Comments

Jackson Center, PA, July 20, 2023 -- Halberd Corporation (OTC: HALB). During the second quarter 2023 Halberd continued its groundbreaking work on its path to creating new technology products and safe, yet effective treatments for previously considered incurable or difficult-to-treat diseases. 2nd QUARTER 2023 ACHIEVEMENTS Mississippi State University (MSU) is well on their way in ...

Apr 25 2023

Halberd Corporation 1Q23 CEO Letter

By |2023-04-24T20:53:26-04:00April 25th, 2023|Investor News, News, Press Releases, Update Letter|0 Comments

Jackson Center, PA, April 25, 2023 -- Halberd Corporation (OTC: HALB). The first quarter 2023 continued this extraordinarily groundbreaking path, packed with new accomplishments. 1st QUARTER 2023 ACHIEVEMENTS Halberd researchers received from the CDC (Centers for Disease Control and Prevention) an array of antibiotic-resistant bacteria (ARB) and deadly fungi for testing. Halberd’s laser eradication application ...

Jan 3 2023

Halberd Corporation 2022 Year End CEO Letter and 2023 Goals

By |2023-01-02T20:07:25-05:00January 3rd, 2023|Featured, Investor News, Press Releases, Update Letter|0 Comments

Profound Advancements Explained Jackson Center, PA, January 3, 2023 -- Halberd Corporation (OTC: HALB) The second half of 2022 was a very busy time. 2022 2nd HALF ACHIEVEMENTS Halberd’s previous research on development of a monoclonal antibody (mAb) against COVID-19 (SARS-COV-2) was found to enhance the effectiveness of the leading commercial COVID antibody by 44.4%. ...

Jul 12 2022

Halberd Corporation Update, CEO Letter and 2022 Expectations

By |2022-07-11T19:19:34-04:00July 12th, 2022|Featured, Investor News, News, Press Releases|0 Comments

Q2 Accomplishments and a Look to the Future Jackson Center, PA, July 12, 2022.  Halberd Corporation (OTC: HALB) This past quarter has witnessed some very significant technical and organizational achievements by the Halberd team.  The accomplishments for the Second Quarter ending June 30, 2022, are as follows: 2Q ACHIEVEMENTS Added an animal testing expert (DVM/PhD) ...

Apr 25 2022

Halberd CEO Letter

By |2022-04-24T18:20:33-04:00April 25th, 2022|Featured, Investor News, News, Press Releases, Update Letter|0 Comments

Q1 Accomplishments and Q2 Plans Jackson Center, PA, April 25, 2022 Greetings From The CEO And Staff At HALBERD CORPORATION! (OTC: HALB) This past quarter has witnessed some very significant technical and organizational achievements by the Halberd team. Q1 OVERVIEW AND ACHIEVEMENTS Halberd demonstrated elimination of the final two of the “Top Ten” antigens linked ...

Jan 25 2022

Halberd CEO Letter: 2021 Year-End & 2022 Outlook

By |2022-01-24T18:26:05-05:00January 25th, 2022|Investor News, Press Releases, Update Letter|0 Comments

Jackson Center, PA, January 25, 2022 Greetings From The CEO And Staff At HALBERD CORPORATION! (OTC: HALB) First of all I want to wish all of our shareholders and constituents a Very Healthy, Happy and Prosperous New Year! 2021 OVERVIEW AND ACHIEVEMENTS Halberd continued its R&D strategy to focus on biomedical areas where: There is ...

Oct 7 2021

Halberd Corporation CEO Letter

By |2021-10-04T21:24:09-04:00October 7th, 2021|Featured, Investor News, News|0 Comments

Q3-21 Accomplishments and Q4 Plans Jackson Center, PA, October 7, 2021 Greetings From The CEO And Staff At HALBERD CORPORATION! (OTC-PINK: HALB) This past quarter, Halberd has made some very significant and unparalleled achievements developing treatments for neurodegenerative diseases, such as PTSD/ CTE (Post Traumatic Stress Disorder/Chronic Traumatic Encephalopathy), Alzheimer’s Disease, Parkinson’s Disease, etc. As ...

Apr 6 2021

Halberd Corporation CEO Letter

By |2021-04-05T20:46:11-04:00April 6th, 2021|Featured, Investor News, News|0 Comments

Q1-21 Accomplishments and Q2 Plans Jackson Center, PA, April 6, 2021 Greetings From The CEO And Staff At HALBERD CORPORATION! (OTC-PINK: HALB) It has been a very busy and fruitful first quarter of 2021.  Often, people get so wrapped up in the day-to-day events that we lose sight of just how far we have traveled.  ...

Go to Top